Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BL1107 Low dose · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BL1107 Low dose | EXPERIMENTAL | - |
| BL1107 High dose | EXPERIMENTAL | - |
| Timolol maleate 0.5% | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BL1107 Low dose | DRUG | Dosed twice daily for 28 days. |
| BL1107 High dose | DRUG | Dosed twice daily for 28 days. |
| Timolol maleate 0.5% | DRUG | Dosed twice daily for 28 days. |
Inclusion criteria: * Ocular hypertension or primary open-angle glaucoma in each eye Exclusion criteria: * History of orthostatic hypotension * Any active ocular disease * Anticipated wearing of contact lenses during study * Contraindication to pupil dilation
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
BL1107 Low dose is an investigational small molecule eye drop being studied for the treatment of glaucoma. It is being developed for patients with primary open angle glaucoma or ocular hypertension, with the goal of lowering intraocular pressure. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
The specific molecular target of BL1107 Low dose has not been disclosed. It is a small molecule administered as an eye drop, intended for use in ophthalmology to treat glaucoma. The mechanism of action is not publicly detailed, and no target class has been specified in available information.
BL1107 Low dose is being developed by Bausch + Lomb Corporation, a company traded on the stock exchange under the ticker symbol BLCO. Bausch + Lomb is responsible for the clinical development of this investigational glaucoma treatment, which is currently in Phase 2 trials.
BL1107 Low dose is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied for the treatment of glaucoma, and its safety and efficacy are still being evaluated in clinical trials.
BL1107 Low dose has one completed Phase 2 clinical trial, identified by the identifier NCT07168902. This study was a randomized, double-blind, active-controlled trial comparing BL1107 eye drops to timolol in adults with primary open angle glaucoma or ocular hypertension. The trial enrolled 252 participants in the United States.
BL1107 Low dose is a specific formulation or dosage strength of the investigational drug BL1107. The name indicates a lower dose version of the compound. Both refer to the same active pharmaceutical ingredient, but BL1107 Low dose is distinguished by its lower concentration, which is being evaluated in clinical trials for glaucoma.